Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of this pathway, and its inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Amy B., Newsome, Dave, Wang, Yuxin, Boucher, Diane M., Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac A., Milton, Sean, Murphy, Cheryl E., Takemoto, Darin, Tolman, Crystal, Wood, Mark, Charlton, Peter, Charrier, Jean-Damien, Furey, Brinley, Golec, Julian, Reaper, Philip M., Pollard, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170644/
https://www.ncbi.nlm.nih.gov/pubmed/25010037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170644/
https://www.ncbi.nlm.nih.gov/pubmed/25010037

Ejemplares similares